RAPT Therapeutics Deepens Expertise in Allergic Diseases with Appointment of Jessica Savage, M.D., M.H.S., as Vice President, Clinical Development
RAPT Therapeutics (RAPT) has appointed Dr. Jessica Savage as Vice President of Clinical Development to lead the development of RPT904, a novel monoclonal antibody targeting immunoglobin E (IgE) for allergic diseases. The company plans to initiate a Phase 2b clinical trial for food allergy in the second half of 2025, with additional focus on chronic spontaneous urticaria (CSU).
Dr. Savage, a board-certified allergist and immunologist, brings significant expertise in food allergy research and clinical development. Her previous experience includes roles at Harvard Medical School, Johns Hopkins University, and leadership positions at Alexion, where she led clinical development strategies for various treatments. She was also involved in development programs for medications like Empaveli®, Trikafta®, and Bylvay®.
RAPT Therapeutics (RAPT) ha nominato la Dott.ssa Jessica Savage Vicepresidente dello Sviluppo Clinico per guidare lo sviluppo di RPT904, un nuovo anticorpo monoclonale che mira all'immunoglobulina E (IgE) per le malattie allergiche. L'azienda prevede di avviare una fase 2b di sperimentazione clinica per l'allergia alimentare nella seconda metà del 2025, con un ulteriore focus sull'orticaria cronica spontanea (CSU).
La Dott.ssa Savage, allergologa e immunologa certificata, porta con sé una significativa esperienza nella ricerca sulle allergie alimentari e nello sviluppo clinico. In passato ha ricoperto ruoli presso la Harvard Medical School, la Johns Hopkins University e posizioni di leadership in Alexion, dove ha guidato strategie di sviluppo clinico per diversi trattamenti. È stata inoltre coinvolta in programmi di sviluppo per farmaci come Empaveli®, Trikafta® e Bylvay®.
RAPT Therapeutics (RAPT) ha nombrado a la Dra. Jessica Savage como Vicepresidenta de Desarrollo Clínico para liderar el desarrollo de RPT904, un nuevo anticuerpo monoclonal dirigido a la inmunoglobulina E (IgE) para enfermedades alérgicas. La compañía planea iniciar un ensayo clínico de fase 2b para alergia alimentaria en la segunda mitad de 2025, con un enfoque adicional en la urticaria crónica espontánea (CSU).
La Dra. Savage, alergóloga e inmunóloga certificada, aporta una amplia experiencia en investigación sobre alergias alimentarias y desarrollo clínico. Su experiencia previa incluye cargos en la Harvard Medical School, Johns Hopkins University y puestos de liderazgo en Alexion, donde dirigió estrategias de desarrollo clínico para varios tratamientos. También participó en programas de desarrollo de medicamentos como Empaveli®, Trikafta® y Bylvay®.
RAPT Therapeutics (RAPT)는 알레르기 질환을 위한 면역글로불린 E(IgE)를 표적으로 하는 새로운 단일클론항체 RPT904의 개발을 이끌 임상개발 부사장으로 제시카 새비지 박사를 임명했습니다. 회사는 2025년 하반기에 식품 알레르기 대상의 2b상 임상시험을 시작할 계획이며, 만성 특발성 두드러기(CSU)에도 추가로 집중할 예정입니다.
새비지 박사는 알레르기 및 면역학 전문의로서 식품 알레르기 연구와 임상개발 분야에서 풍부한 경험을 갖고 있습니다. 그녀는 하버드 의과대학, 존스 홉킨스 대학교에서 근무했으며, Alexion에서 다양한 치료제의 임상개발 전략을 이끄는 리더십 역할을 수행했습니다. 또한 Empaveli®, Trikafta®, Bylvay® 등의 약물 개발 프로그램에도 참여했습니다.
RAPT Therapeutics (RAPT) a nommé le Dr Jessica Savage au poste de vice-présidente du développement clinique pour diriger le développement de RPT904, un nouvel anticorps monoclonal ciblant l’immunoglobuline E (IgE) pour les maladies allergiques. La société prévoit de lancer un essai clinique de phase 2b pour l’allergie alimentaire au second semestre 2025, avec un accent supplémentaire sur l’urticaire chronique spontanée (CSU).
Le Dr Savage, allergologue et immunologiste certifiée, apporte une expertise significative en recherche sur les allergies alimentaires et en développement clinique. Elle a précédemment occupé des postes à la Harvard Medical School, à l’Université Johns Hopkins, ainsi que des fonctions de direction chez Alexion, où elle a piloté les stratégies de développement clinique pour divers traitements. Elle a également participé à des programmes de développement de médicaments tels qu’Empaveli®, Trikafta® et Bylvay®.
RAPT Therapeutics (RAPT) hat Dr. Jessica Savage zur Vizepräsidentin für klinische Entwicklung ernannt, um die Entwicklung von RPT904, einem neuartigen monoklonalen Antikörper gegen Immunglobulin E (IgE) bei allergischen Erkrankungen, zu leiten. Das Unternehmen plant, in der zweiten Hälfte des Jahres 2025 eine Phase-2b-Studie zur Nahrungsmittelallergie zu starten, mit zusätzlichem Fokus auf chronische spontane Urtikaria (CSU).
Dr. Savage, eine zertifizierte Allergologin und Immunologin, bringt umfassende Expertise in der Forschung zu Nahrungsmittelallergien und der klinischen Entwicklung mit. Ihre bisherige Erfahrung umfasst Positionen an der Harvard Medical School, der Johns Hopkins University sowie Führungsrollen bei Alexion, wo sie klinische Entwicklungsstrategien für verschiedene Therapien leitete. Sie war zudem an Entwicklungsprogrammen für Medikamente wie Empaveli®, Trikafta® und Bylvay® beteiligt.
- Appointment of experienced allergist/immunologist with expertise in food allergy development
- Advancement to Phase 2b clinical trials for RPT904 in 2025
- Potential expansion into multiple allergic disease indications
- Phase 2b trials not starting until second half of 2025
- Early-stage development status with no immediate revenue potential
SOUTH SAN FRANCISCO, Calif., April 15, 2025 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based biopharmaceutical company focused on discovering, developing and commercializing novel therapies for patients living with inflammatory and immunological diseases, today announced the appointment of Jessica Savage, M.D., M.H.S., as Vice President, Clinical Development to oversee the development of RPT904, a novel, half-life extended monoclonal antibody designed to bind free human immunoglobin E (“IgE”), a key driver of several allergic diseases. RAPT plans to pursue development of RPT904 initially in food allergy and chronic spontaneous urticaria (“CSU”).
“We are thrilled to welcome Jessica to the RAPT leadership team at this pivotal time for the company,” said Brian Wong, M.D., Ph.D., President and CEO of RAPT. “With her deep expertise as both an allergist and immunologist, and particularly her experience in food allergy, she will be instrumental in advancing RPT904 to a Phase 2b clinical trial for food allergy in the second half of 2025 and generating important data to differentiate RPT904 as an attractive therapeutic option for patients.”
Dr. Savage added, “I am excited to join RAPT and apply my experience and expertise to the development of RPT904, which I believe has promise as a best-in-class drug for patients with food allergy. Food allergy is a large and underappreciated health problem affecting millions of people. There is a clear unmet need, and I appreciate the opportunity to be part of an innovative solution. I look forward to initiating our clinical trial and planning for eventual approval in food allergy, CSU and possibly other allergic diseases.”
Jessica Savage, M.D., M.H.S.
Dr. Savage is a board-certified allergist and immunologist with early- and late-stage clinical development experience, and expertise in food allergy. She has played important roles in multiple global development programs. Dr. Savage held faculty, research and clinical roles at Harvard Medical School, Brigham and Women’s Hospital and Johns Hopkins University School of Medicine, where she focused on food allergy and allergic diseases and was the lead author of a study of omalizumab in patients with peanut allergy. More recently, she served as Senior Medical Director at Alexion, AstraZeneca’s Rare Disease Unit, where she led the clinical development strategy for ALXN2050 in Lupus Nephritis and IgA Nephropathy, overseeing Phase 2 clinical trial execution and preparing for Phase 3. Previously, Dr. Savage served as Clinical Development Lead for the sNDA of Empaveli® (pegcetacoplan) and contributed to the NDAs for Trikafta® (elexacaftor/tezacaftor/ivacaftor and ivacaftor) and Bylvay® (odevixibat) while at Apellis Pharmaceuticals, Vertex Pharmaceuticals, and Albireo Pharma, respectively. She earned her M.D. and M.H.S. from the Johns Hopkins University School of Medicine and Johns Hopkins University Bloomberg School of Public Health, respectively, and completed a fellowship in Allergy and Clinical Immunology at the Johns Hopkins Hospital under the mentorship of Dr. Robert Wood.
About RAPT Therapeutics, Inc.
RAPT Therapeutics is a clinical-stage immunology-based biopharmaceutical company focused on discovering, developing and commercializing novel therapies for patients living with inflammatory and immunological diseases. Utilizing our deep and proprietary expertise in immunology, we develop novel therapies that are designed to modulate the critical immune responses underlying these diseases.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as “anticipate,” “estimates,” “expects,” “will” and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) are intended to identify forward-looking statements. These statements relate to future events and involve known and unknown risks, uncertainties and other factors that may cause our actual results, performance or achievements to be materially different from any future performances or achievements expressed or implied by the forward-looking statements. Each of these statements is based only on current information, assumptions and expectations that are inherently subject to change and involve a number of risks and uncertainties. Forward-looking statements include, but are not limited to, statements about the therapeutic potential of RPT904 and development plans for RPT904, including the timing of the initiation of clinical trials, and other statements that are not historical fact. Many factors may cause differences between current expectations and actual results, including unexpected or unfavorable safety or efficacy data observed during clinical studies, preliminary data and trends that may not be predictive of future data or results or that may not demonstrate safety or efficacy or lead to regulatory approval, clinical trial site activation or enrollment rates that are lower than expected, unanticipated or greater than anticipated impacts or delays due to macroeconomic and geopolitical conditions (including the long-term impacts of ongoing overseas conflicts, fluctuations in inflation and interest rates and other economic uncertainty), changes in expected or existing competition, changes in the regulatory environment, the uncertainties and timing of the regulatory approval process and the sufficiency of RAPT’s cash resources. Detailed information regarding risk factors that may cause actual results to differ materially from the results expressed or implied by statements in this press release may be found in RAPT’s Annual Report on Form 10-K filed with the Securities and Exchange Commission on March 6, 2025 and subsequent filings made by RAPT with the Securities and Exchange Commission. These forward-looking statements speak only as of the date hereof. RAPT disclaims any obligation to update these forward-looking statements, except as required by law.
RAPT Investor Contact:
Sylvia Wheeler
swheeler@wheelhouselsa.com
RAPT Media Contact:
Aljanae Reynolds
areynolds@wheelhouselsa.com
FAQ
When will RAPT Therapeutics begin Phase 2b trials for RPT904 in food allergy?
What conditions will RAPT's RPT904 treatment target initially?
What is the mechanism of action for RAPT's RPT904 drug?
What is Dr. Jessica Savage's role at RAPT Therapeutics?
